Groundbreaking Clinical Results for Kelun-Biotech’s ADC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has recently shared promising findings regarding their innovative TROP2 antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT). The findings emerged from significant clinical trials aimed at evaluating sac-TMT for adult patients battling advanced triple-negative breast cancer (TNBC) and also for those with advanced non-small-cell lung cancer (NSCLC). These results were celebrated in the esteemed journal Nature Medicine, known for showcasing leading medical research.
Efficacy in Treating Triple-Negative Breast Cancer
The Phase 3 OptiTROP-Breast01 study provided valuable insights into the effectiveness of sac-TMT. As part of a multicenter, randomized, controlled design, researchers assessed the performance of sac-TMT in comparison to standard chemotherapy regimens chosen by investigators. The outcomes stuck with the clinical community—sac-TMT presented significant enhancements in both progression-free survival (PFS) and overall survival (OS), showcasing its potential as a superior option for patients with locally advanced or metastatic TNBC. Following this success, the product received market approval for patients who had undergone at least two prior systemic therapies.
Presentation Highlights
The successful results were formally presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, marking a pivotal milestone for Kelun-Biotech and the medical landscape it aims to enhance.
Insights for Non-Small Cell Lung Cancer Treatment
In addition to findings related to TNBC, the publication also illuminated the results from early Phase I/II studies addressing NSCLC. These investigations underscored the efficacy and safety of sac-TMT in advanced NSCLC, irrespective of the presence of epidermal growth factor receptor (EGFR) mutations. The authors also delved into laboratory analyses that hinted at the mechanisms behind sac-TMT’s potential, suggesting that EGFR mutations may heighten anti-tumor effects through enhanced endocytosis.
Leadership Acknowledgment
Dr. Michael Ge, CEO of Kelun-Biotech, commented on these significant findings, emphasizing that such recognition from an internationally revered journal underlines the clinical effectiveness of sac-TMT. Underlining the company's unyielding dedication to innovation, Dr. Ge expressed enthusiasm for ongoing research initiatives in the ADC domain with their collaborator, MSD.
Understanding sac-TMT’s Unique Mechanism
As a leading product in Kelun-Biotech’s portfolio, sac-TMT is achieving a notable reputation. This human TROP2 ADC was developed to target advanced solid tumors, including NSCLC and breast cancer. One of the remarkable aspects of sac-TMT is its unique design, featuring a specialized linker that conjugates the payload—a topoisomerase I inhibitor derived from belotecan—with a favorable drug-to-antibody ratio (DAR) of 7.4.
The ADC is crafted to specifically recognize TROP2 located on tumor cell membranes. Once an antibody binds to the tumor, it facilitates cell entry and releases KL610023 within the cells, resulting in DNA damage that can halt cell division and trigger programmed cell death. Furthermore, because KL610023 is membrane permeable, it can even target adjacent tumor cells, potentially broadening its therapeutic reach.
Future Directions for sac-TMT
Kelun-Biotech has already made strides in the marketing of sac-TMT in China, receiving approvals for its use among adult patients with specific TNBC cases and EGFR mutation-positive NSCLC. Notably, sac-TMT stands out as the first domestic ADC globally to achieve full approval for marketing, embodying a significant advance not only for the company but also for cancer therapy innovation.
Looking ahead, Kelun-Biotech has embarked on an ambitious path with eight registrational clinical studies in progress. MSD has joined hands with Kelun-Biotech for twelve Phase 3 global clinical studies to explore the efficacy of sac-TMT as a standalone therapy or in combination with other agents like pembrolizumab for various cancer types.
About Kelun-Biotech
Kelun-Biotech (6990.HK), a subsidiary of Kelun Pharmaceutical (002422.SZ), is devoted to the development, manufacturing, and commercialization of cutting-edge therapeutic solutions. With a strong focus on critical health challenges such as solid tumors and autoimmune conditions, the company is establishing a comprehensive platform aimed at addressing unmet medical needs locally and around the globe. Their commitment to becoming a top-tier global entity in the innovative drug sector is evident, and with over 30 ongoing projects and multiple ADC initiatives, they are at the forefront of advancing medical treatment options.
Frequently Asked Questions
What is sacituzumab tirumotecan?
Sacituzumab tirumotecan (sac-TMT) is a novel TROP2 antibody-drug conjugate developed by Kelun-Biotech, targeting advanced tumors.
What cancers does sac-TMT aim to treat?
Sac-TMT is primarily focused on advanced triple-negative breast cancer (TNBC) and non-small-cell lung cancer (NSCLC).
What were the results of the Phase 3 study?
The Phase 3 study showed significant improvements in both progression-free survival and overall survival compared to standard chemotherapy.
What are the potential mechanisms of action for sac-TMT?
The treatment harnesses the body's mechanisms to enhance tumor targeting and induces cell death through DNA damage.
How is Kelun-Biotech advancing its research?
Kelun-Biotech is actively conducting multiple clinical studies and collaborating with MSD for further development of sac-TMT.
